Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells

Proteomics

Volumn 15, Issue 4, 2015, Pages 824-835

  Jung, Jae Hun ^a   Lee, Min Young ^a   Choi, Do Young ^a   Lee, Jae Won ^a   You, Sungyong ^b   Lee, Kye Young ^c   Kim, Jayoung ^b   Kim, Kwang Pyo ^a  

^a Kyung Hee University   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Konkuk University Hospital   (South Korea)

Author keywords

Extracellular vesicles; Lipidopmics; MALDI MS; Nonsmall cell lung cancer; Phospholipids

Indexed keywords

GEFITINIB; HYDROGEN; LIPIDOME; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; SODIUM; SPHINGOMYELIN; ANTINEOPLASTIC AGENT; CELL EXTRACT; QUINAZOLINE DERIVATIVE;

ALGORITHM; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CULTURE; CELL ISOLATION; CELL LYSATE; CELL VACUOLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DISEASE ASSOCIATION; DRUG SENSITIVITY; EXTRACELLULAR VESICLE; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNOBLOTTING; IONIZATION; LIPID ANALYSIS; LIPID COMPOSITION; LIPIDOMICS; LUNG CANCER CELL LINE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NON SMALL CELL LUNG CANCER; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; WHOLE CELL; CHEMISTRY; CYTOPLASM VESICLE; DRUG EFFECTS; DRUG RESISTANCE; EXTRACELLULAR SPACE; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL EXTRACTS; CELL LINE, TUMOR; CYTOPLASMIC VESICLES; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SPACE; HUMANS; PHOSPHOLIPIDS; QUINAZOLINES;

EID: 84940583132     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400243     Document Type: Article

References (63)

1. Ulivi, P., Zoli, W., Capelli, L., Chiadini, E. et al., Target therapy in NSCLC patients: relevant clinical agents and tumour molecular characterisation. Mol. Clin. Oncol. 2013, 1, 575-581.
2. Rosell, R., Bivona, T. G., Karachaliou, N., Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013, 382, 720-731.
3. Petrelli, F., Borgonovo, K., Cabiddu, M., Barni, S., Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin. Lung Cancer 2012, 13, 107-114.
4. Pirker, R., Novel drugs against non-small-cell lung cancer. Curr. Opin. Oncol. 2014, 26, 145-151.
5. Bauml, J., Mick, R., Zhang, Y., Watt, C. D. et al., Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies. Clin. Lung Cancer 2013, 14, 581-591.
6. Choi, D. S., Yang, J. S., Choi, E. J., Jang, S. C. et al., The protein interaction network of extracellular vesicles derived from human colorectal cancer cells. J. Proteome Res. 2012, 11, 1144-1151.
7. Choi, D. S., Lee, J. M., Park, G. W., Lim, H. W. et al., Proteomic analysis of microvesicles derived from human colorectal cancer cells. J. Proteome Res. 2007, 6, 4646-4655.
8. Kim, D. K., Kang, B., Kim, O. Y., Choi, D. S. et al., EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles. J. Extracell Vesicles 2013, 2.
9. Choi, D. S., Choi, D. Y., Hong, B. S., Jang, S. C. et al., Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells. J. Extracell Vesicles 2012, 1.
10. Kim, J., Morley, S., Le, M., Bedoret, D. et al., Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: potential effects on the tumor microenvironment. Cancer Biol. Ther. 2014, 15, 409-418.
11. Chen, W. X., Zhong, S. L., Ji, M. H., Pan, M. et al., MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol. 2014, 35, 2883-2892.
12. Inal, J. M., Kosgodage, U., Azam, S., Stratton, D. et al., Blood/plasma secretome and microvesicles. Biochim. Biophys. Acta 2013, 1834, 2317-2325.
13. Principe, S., Hui, A. B., Bruce, J., Sinha, A. et al., Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics 2013, 13, 1608-1623.
14. Muralidharan-Chari, V., Clancy, J. W., Sedgwick, A., D'Souza-Schorey, C., Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 2010, 123, 1603-1611.
15. Voloshin, T., Fremder, E., Shaked, Y., Small but mighty: microparticles as mediators of tumor progression. Cancer Microenviron. 2014, 1-2, 11-21.
16. Choi, D. Y., You, S., Jung, J. H., Lee, J. C. et al., Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Proteomics 2014, 14, 1845-1856.
17. Kang, S., Lee, A., Park, Y. S., Lee, S. C. et al., Alteration in lipid and protein profiles of ovarian cancer: similarity to breast cancer. Int. J. Gynecol. Cancer 2011, 21, 1566-1572.
18. Kim, I. C., Lee, J. H., Bang, G., Choi, S. H. et al., Lipid profiles for HER2-positive breast cancer. Anticancer Res. 2013, 33, 2467-2472.
19. Kim, Y., Shanta, S. R., Zhou, L. H., Kim, K. P., Mass spectrometry based cellular phosphoinositides profiling and phospholipid analysis: a brief review. Exp. Mol. Med. 2010, 42, 1-11.
20. Kim, K. P., Rafter, J. D., Bittova, L., Han, S. K. et al., Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils. A potential role of heparan sulfate binding in PLA2 internalization and degradation. J. Biol. Chem. 2001, 276, 11126-11134.
21. Aboagye, E. O., Bhujwalla, Z. M., Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999, 59, 80-84.
22. Bogin, L., Papa, M. Z., Polak-Charcon, S., Degani, H., TNF-induced modulations of phospholipid metabolism in human breast cancer cells. Biochim. Biophys. Acta 1998, 1392, 217-232.
23. Ronen, S. M., Leach, M. O., Imaging biochemistry: applications to breast cancer. Breast Cancer Res. 2001, 3, 36-40.
24. Zhu, L., Johnson, C., Bakovic, M., Stimulation of the human CTP: phosphoethanolamine cytidylyltransferase gene by early growth response protein 1. J. Lipid Res. 2008, 49, 2197-2211.
25. Smith, E. L., Schuchman, E. H., The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J. 2008, 22, 3419-3431.
26. Cummings, B. S., Phospholipase A2 as targets for anti-cancer drugs. Biochem. Pharmacol. 2007, 74, 949-959.
27. Inazu, M., Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy. Biopharm. Drug Dispos. 2014, 35(8), 431-449.
28. Volinsky, R., Kinnunen, P. K., Oxidized phosphatidylcholines in membrane-level cellular signaling: from biophysics to physiology and molecular pathology. FEBS J. 2013, 280, 2806-2816.
29. Monteiro-Cardoso, V. F., Silva, A. M., Oliveira, M. M., Peixoto, F., Videira, R. A., Membrane lipid profile alterations are associated with the metabolic adaptation of the Caco-2 cells to aglycemic nutritional condition. J. Bioenerg. Biomembr. 2014, 46, 45-57.
30. Jones, D. R., Divecha, N., Linking lipids to chromatin. Curr. Opin. Genet. Dev. 2004, 14, 196-202.
31. Doria, M. L., Cotrim, Z., Macedo, B., Simoes, C. et al., Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells. Breast Cancer Res. Treat. 2012, 133, 635-648.
32. Shanta, S. R., Zhou, L. H., Park, Y. S., Kim, Y. H. et al., Binary matrix for MALDI imaging mass spectrometry of phospholipids in both ion modes. Anal. Chem. 2011, 83, 1252-1259.
33. Separovic, D., Joseph, N., Breen, P., Bielawski, J. et al., Combining anticancer agents photodynamic therapy and LCL85 leads to distinct changes in the sphingolipid profile, autophagy, caspase-3 activation in the absence of cell death, and long-term sensitization. Biochem. Biophys. Res. Commun. 2011, 409, 372-377.
34. Jones, E. E., Powers, T. W., Neely, B. A., Cazares, L. H. et al., MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics 2014, 14, 924-935.
35. Schone, C., Hofler, H., Walch, A., MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. Clin. Biochem. 2013, 46, 539-545.
36. Choi, D. S., Kim, D. K., Kim, Y. K., Gho, Y. S., Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 2013, 10-11, 1544-1571.
37. Bligh, E. G., Dyer, W. J., A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37, 911-917.
38. Edwards, J. L., Kennedy, R. T., Metabolomic analysis of eukaryotic tissue and prokaryotes using negative mode MALDI time-of-flight mass spectrometry. Anal. Chem. 2005, 77, 2201-2209.
39. Gibb, S., Strimmer, K., MALDIquant: a versatile R package for the analysis of mass spectrometry data. Bioinformatics 2012, 28, 2270-2271.
40. Dieterle, F., Ross, A., Schlotterbeck, G., Senn, H., Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal. Chem. 2006, 78, 4281-4290.
41. Xia, J., Wishart, D. S., Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat. Protoc. 2011, 6, 743-760.
42. Lee, G. K., Lee, H. S., Park, Y. S., Lee, J. H. et al., Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type. Lung Cancer 2012, 76, 197-203.
43. Dill, A. L., Ifa, D. R., Manicke, N. E., Costa, A. B. et al., Lipid profiles of canine invasive transitional cell carcinoma of the urinary bladder and adjacent normal tissue by desorption electrospray ionization imaging mass spectrometry. Anal. Chem. 2009, 81, 8758-8764.
44. Son, J., Lee, G., Cha, S., Direct analysis of triacylglycerols from crude lipid mixtures by gold nanoparticle-assisted laser desorption/ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 2014, 25, 891-894.
45. Sudano, M. J., Santos, V. G., Tata, A., Ferreira, C. R. et al., Phosphatidylcholine and sphingomyelin profiles vary in Bos taurus indicus and Bos taurus taurus in vitro- and in vivo-produced blastocysts. Biol. Reprod. 2012, 87, 130.
46. Park, Y. S., Yoo, C. W., Lee, S. C., Park, S. J. et al., Lipid profiles for intrahepatic cholangiocarcinoma identified using matrix-assisted laser desorption/ionization mass spectrometry. Clin. Chim. Acta 2011, 412, 1978-1982.
47. Thomas, M. C., Mitchell, T. W., Blanksby, S. J., A comparison of the gas phase acidities of phospholipid headgroups: experimental and computational studies. J. Am. Soc. Mass Spectrom. 2005, 16, 926-939.
48. Taniguchi, M., Okazaki, T., The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration-from cell and animal models to human disorders. Biochim. Biophys. Acta 2014, 1841, 692-703.
49. Barcelo-Coblijn, G., Martin, M. L., de Almeida, R. F., Noguera-Salva, M. A. et al., Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc. Natl. Acad. Sci. USA 2011, 108, 19569-19574.
50. Savic, R., He, X., Fiel, I., Schuchman, E. H., Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. PLoS One 2013, 8, e65620.
51. Cheng, J. C., Bai, A., Beckham, T. H., Marrison, S. T. et al., Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J. Clin. Invest. 2013, 123, 4344-4358.
52. Lin, H. Y., Delmas, D., Vang, O., Hsieh, T. C. et al., Mechanisms of ceramide-induced COX-2-dependent apoptosis in human ovarian cancer OVCAR-3 cells partially overlapped with resveratrol. J. Cell Biochem. 2013, 114, 1940-1954.
53. Freeman, M. R., Cinar, B., Kim, J., Mukhopadhyay, N. K. et al., Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids 2007, 72, 210-217.
54. Balla, T., Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol. Rev. 2013, 93, 1019-1137.
55. Song, Y., Wilkins, P., Hu, W., Murthy, K. S. et al., Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem. J. 2007, 406, 427-436.
56. Smrcka, A. V., Brown, J. H., Holz, G. G., Role of phospholipase Cepsilon in physiological phosphoinositide signaling networks. Cell Signal. 2012, 24, 1333-1343.
57. Samadi, N., Bekele, R., Capatos, D., Venkatraman, G. et al., Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 2011, 93, 61-70.
58. Bruntz, R. C., Taylor, H. E., Lindsley, C. W., Brown, H. A., Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J. Biol. Chem. 2014, 289, 600-616.
59. Musille, P. M., Kohn, J. A., Ortlund, E. A., Phospholipid-driven gene regulation. FEBS Lett. 2013, 587, 1238-1246.
60. Paris, L., Cecchetti, S., Spadaro, F., Abalsamo, L. et al., Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res. 2010, 12, R27.
61. Iorio, E., Mezzanzanica, D., Alberti, P., Spadaro, F. et al., Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005, 65, 9369-9376.
62. Gallego-Ortega, D., Ramirez de Molina, A., Ramos, M. A., Valdes-Mora, F. et al., Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One 2009, 4, e7819.
63. Llorente, A., Skotland, T., Sylvanne, T., Kauhanen, D. et al., Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim. Biophys. Acta 2013, 1831, 1302-1309.